ការតាំងទីលំនៅ Opioid អូស Walgreens ដល់ការខាតបង់ 3.7 ពាន់លានដុល្លារ

Walgreens Boots Alliance reported a $3.7 billion loss to cover its share of a massive global settlement of claims its pharmacies contributed to the opioid epidemic.

Walgreens Thursday disclosed a $3.7 billion net loss, or $4.31 a share, for its fiscal first quarter 2023, which ended November 30, 2022. That was well off the year-ago period when Walgreens earned a net profit of $3.58 billion, or $4.13 a share.

“First quarter loss per share was $4.31 compared to earnings per share of $4.13 in the year-ago quarter reflecting a $6.5 billion pre-tax charge recognized in connection with the previously announced opioid litigation settlement frameworks and certain other opioid-related matters,” Walgreens said Wednesday in its quarterly earnings report.

CVS, Walgreens and Walmart – the nation’s three largest retail U.S. pharmacy chains — agreed in November to pay more than $13 billion in a massive global settlement to resolve claims they contributed to the opioid epidemic. មជ្ឈមណ្ឌលគ្រប់គ្រងនិងបង្ការជំងឺសហរដ្ឋអាមេរិក ការប៉ាន់ប្រមាណថាវិបត្តិអាភៀនទូទាំងប្រទេសបាននាំឱ្យមានការស្លាប់ជាងកន្លះលាននាក់ពីការប្រើថ្នាំជ្រុលក្នុងរយៈពេល 20 ឆ្នាំចុងក្រោយនេះ។ Walmart, CVS និង Walgreens រួមបញ្ចូលគ្នាមានឱសថស្ថានអាមេរិកជាង 23,000 ។

ការស៊ើបអង្កេតដោយមេធាវីរដ្ឋ និងសហព័ន្ធ ក៏ដូចជាមេធាវីក្នុងការអនុវត្តឯកជនដែលតំណាងឱ្យក្រុមគ្រួសារនៃជនរងគ្រោះដោយអាភៀនបានលើកឡើងពីតួនាទីរបស់អ្នកចែកចាយ និងឱសថស្ថានក្នុងការរាតត្បាត។ A ឆ្នាំ 2019 របាយការណ៍ស៊ើបអង្កេតនៅក្នុង Washington Post បាននិយាយថា Walgreens "បានដោះស្រាយជិតមួយក្នុងចំណោម XNUMX នៃការញៀនអាភៀនបំផុត" នៅកំពូលនៃវិបត្តិជុំវិញថ្នាំបំបាត់ការឈឺចាប់ និង ដើរតួជា "អ្នកចែកចាយផ្ទាល់ខ្លួន" ។

Along with the quarterly loss, Walgreens Thursday reported sales dipped 1.5% to $33.4 billion as the company transitions from a pharmacy chain to what its top executive calls a “consumer-centric healthcare company.”

“We’re making significant progress in driving our U.S. Healthcare segment to scale and profit, including the recent VillageMD acquisition of Summit Health,” Walgreens Chief Executive Officer Rosalind Brewer said in a statement accompanying the earnings report. “Our core retail pharmacy businesses in both the United States and United Kingdom remain resilient in challenging operating environments. Execution across segments reinforces our confidence in achieving full-year guidance, and our strategic actions are creating long-term shareholder value.”

Walgreens raised its full-year sales guidance to $133.5 billion to $137.5 billion reflecting its “Summit Health acquisition, refreshed currency rates, and first quarter sales ahead of expectations,” the company said.

During the quarter, Walgreens invested $3.5 billion in debt and equity to support doctor-staffed clinic operator VillageMD’s acquisition of Summit Health, which closed January 3 of this year. Walgreens-backed VillageMD is buying Summit Health for $8.9 billion to expand doctor-staffed clinics across the country.

ប្រតិបត្តិការ រួមបញ្ចូលការវិនិយោគពី Walgreens ដែលមានជាង 60% នៃ VillageMD រួចហើយ និងក្រុមហ៊ុនធានារ៉ាប់រងសុខភាព Cigna's health services business Evernorth។ អ្នកផ្តល់សេវាថែទាំបឋម Summit Health រួមបញ្ចូលគ្នាជាមួយ CityMD ក្នុងឆ្នាំ 2019 ដើម្បីបង្កើតក្រុមហ៊ុនមួយដែលមានអ្នកផ្តល់សេវាថែទាំសុខភាពច្រើនជាង 1,400 ដែលផ្តល់ការថែទាំបឋម ឯកទេស និងបន្ទាន់។

In the first quarter, Walgreens said its U.S. healthcare segment that includes VillageMD clinics had first quarter sales of $989 million, “an increase of $938 million compared to the prior year period.”

“On a pro forma basis, this segment’s businesses grew sales at a combined rate of 38.4 percent in the quarter,” Walgreens said. “VillageMD grew 48.7 percent, reflecting existing clinic growth and clinic footprint expansion.”

Meanwhile, Walgreens U.S. retail pharmacy segment had first quarter sales of $27.2 billion, which dropped 3% from the year-ago quarter that “included a significant contribution from COVID-19 vaccinations,” the company said.